Ireland

Innocoll Holdings

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

IRELAND Ireland

Post An Enquiry

Virtual Booth

Drug Discovery Chemistry

Participation Not Confirmed

Update your events

Innocoll Holdings Limited Announces FDA Acceptance of New Drug Application for XARACOLL

Lead Product(s): Bupivacaine Hydrochloride

Therapeutic Area: Neurology

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 26, 2020

Details:

If approved, XARACOLL will be Innocoll's first commercially available product in the US.

Jazz Pharmaceuticals

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

IRELAND Ireland

Post An Enquiry

Virtual Booth

Drug Discovery Chemistry

Participation Not Confirmed

Update your events

Jazz Pharmaceuticals Announces FDA Acceptance of New Drug Application for JZP-258

Lead Product(s): Sodium Oxybate

Therapeutic Area: Neurology

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 25, 2020

Details:

JZP-258 represents between 1,000 and 1,500 milligrams daily reduction of sodium for patients currently treated with Xyrem, depending on the dose.

Innocoll Holdings

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

IRELAND Ireland

Post An Enquiry

Virtual Booth

Drug Discovery Chemistry

Participation Not Confirmed

Update your events

Innocoll Holdings Limited Resubmits New Drug Application to FDA for XARACOLL

Lead Product(s): Bupivacaine Hydrochloride

Therapeutic Area: Neurology

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable February 27, 2020

Details:

Innocoll anticipates a 6-month review by the FDA.

Find

Find drug development pipeline and deal Updates information

A collaboration with SCORR Marketing

Product Type

Companies

Innocoll Holdings

Innocoll Holdings Limited Announces FDA Acceptance of New Drug Application for XARACOLL

Jazz Pharmaceuticals

Jazz Pharmaceuticals Announces FDA Acceptance of New Drug Application for JZP-258

Innocoll Holdings

Innocoll Holdings Limited Resubmits New Drug Application to FDA for XARACOLL